Credit: Shutterstock. Crinecerfort is an investigational, oral, selective corticotropin-releasing factor type 1 receptor (CRF1) antagonist. A phase 3 study evaluating the efficacy and safety of ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved crinecerfont to treat patients with congenital adrenal hyperplasia. The drug directly reduces ...

SAN FRANCISCO -- Crinecerfont (Crenessity) may help improve metabolic profiles of adults and children with classic congenital adrenal hyperplasia (CAH), analyses of phase III CAHtalyst trial data ...

The NDA submissions are for 2 formulations of crinecerfont: a capsule and an oral solution. The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Applications (NDA) for ...

BOSTON — Crinecerfont, an investigational oral selective corticotropin-releasing factor type 1 receptor antagonist, benefits both adults and children with congenital adrenal hyperplasia (CAH) due to ...

SAN DIEGO, May 15, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new data from the Phase 3 CAHtalyst™ Adult and Pediatric studies of CRENESSITY™ (crinecerfont). The ...

Crinecerfont was approved for use in combination with glucocorticoids in patients ages 4 years and older with the rare genetic condition that impacts the adrenal glands. Acting as a potent and ...

One-year data from CAHtalyst ™ Adult study demonstrated lasting reductions in glucocorticoid dose and improvement in clinical outcomes in adults with classic congenital adrenal hyperplasia Results ...

Neurocrine Biosciences has announced that the US Food and Drug Administration (FDA) has accepted its two New Drug Applications (NDA) for crinecerfont, granting them Priority Review designations. The ...

Neurocrine Biosciences has reported very positive Phase III results for crinecerfont in adult and pediatric congenital adrenal hyperplasia. The adult study showed that 63% of patients on crinecerfont ...

Please provide your email address to receive an email when new articles are posted on . An investigational nonsteroidal treatment for classic congenital adrenal hyperplasia improved levels of ...